Is Genmab AS Stock a Good Investment?
Genmab AS Investment Advice | GMAB |
- Examine Genmab AS's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Genmab AS's leadership team and their track record. Good management can help Genmab AS navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Genmab AS's business and its evolving consumer preferences.
- Compare Genmab AS's performance and market position to its competitors. Analyze how Genmab AS is positioned in terms of product offerings, innovation, and market share.
- Check if Genmab AS pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Genmab AS's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Genmab AS stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Genmab AS is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Small | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Genmab AS Stock
Researching Genmab AS's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The book value of the company was currently reported as 502.6. The company has Price/Earnings To Growth (PEG) ratio of 0.79. Genmab AS had not issued any dividends in recent years. The entity had 5:1 split on the 1st of May 2018.
To determine if Genmab AS is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Genmab AS's research are outlined below:
| Genmab AS generated a negative expected return over the last 90 days | |
| Genmab AS is unlikely to experience financial distress in the next 2 years | |
| Genmab AS has a strong financial position based on the latest SEC filings | |
| Latest headline from insidermonkey.com: Genmab AS Q3 2024 Earnings Call Transcript |
Genmab AS Quarterly Liabilities And Stockholders Equity |
|
Genmab AS uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Genmab AS. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Genmab AS's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Genmab AS's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Genmab AS's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-08-11 | 2021-06-30 | 0.0723 | 0.08 | 0.0077 | 10 | ||
2021-05-21 | 2021-03-31 | 0.23 | 0.27 | 0.04 | 17 | ||
2024-11-06 | 2024-09-30 | 0.35 | 0.29 | -0.06 | 17 | ||
2019-08-20 | 2019-06-30 | 0.27 | 0.2 | -0.07 | 25 | ||
2021-11-10 | 2021-09-30 | 0.1315 | 0.21 | 0.0785 | 59 | ||
2024-05-02 | 2024-03-31 | 0.14 | 0.29 | 0.15 | 107 | ||
2023-05-10 | 2023-03-31 | 0.65 | 0.05 | -0.6 | 92 | ||
2022-05-11 | 2022-03-31 | 0.91 | 0.11 | -0.8 | 87 |
Know Genmab AS's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Genmab AS is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Genmab AS backward and forwards among themselves. Genmab AS's institutional investor refers to the entity that pools money to purchase Genmab AS's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2024-06-30 | 877.9 K | Royal Bank Of Canada | 2024-06-30 | 792.8 K | Wells Fargo & Co | 2024-06-30 | 723.5 K | Two Sigma Investments Llc | 2024-06-30 | 709.6 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 648.4 K | Voloridge Investment Management, Llc | 2024-06-30 | 528.2 K | Northern Trust Corp | 2024-06-30 | 519.4 K | American Century Companies Inc | 2024-06-30 | 452.2 K | Millennium Management Llc | 2024-06-30 | 381 K | Alliancebernstein L.p. | 2024-06-30 | 15.2 M | Blackrock Inc | 2024-06-30 | 5.1 M |
Genmab AS's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 14.74 B.Market Cap |
|
Genmab AS's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.12 | 0.13 | |
| Return On Capital Employed | 0.16 | 0.17 | |
| Return On Assets | 0.12 | 0.13 | |
| Return On Equity | 0.14 | 0.14 |
Determining Genmab AS's profitability involves analyzing its financial statements and using various financial metrics to determine if Genmab AS is a good buy. For example, gross profit margin measures Genmab AS's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Genmab AS's profitability and make more informed investment decisions.
Please note, the presentation of Genmab AS's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Genmab AS's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Genmab AS's management manipulating its earnings.
Evaluate Genmab AS's management efficiency
Genmab AS has return on total asset (ROA) of 0.1095 % which means that it generated a profit of $0.1095 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1492 %, meaning that it created $0.1492 on every $100 dollars invested by stockholders. Genmab AS's management efficiency ratios could be used to measure how well Genmab AS manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.13. The current year's Return On Capital Employed is expected to grow to 0.17. At present, Genmab AS's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 2.3 B, whereas Non Currrent Assets Other are forecasted to decline to about 41 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 48.40 | 50.82 | |
| Tangible Book Value Per Share | 48.25 | 50.66 | |
| Enterprise Value Over EBITDA | 22.36 | 13.95 | |
| Price Book Value Ratio | 4.44 | 5.81 | |
| Enterprise Value Multiple | 22.36 | 13.95 | |
| Price Fair Value | 4.44 | 5.81 | |
| Enterprise Value | 126.3 B | 132.6 B |
Evaluating the management effectiveness of Genmab AS allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Genmab Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 0.859 |
Basic technical analysis of Genmab Stock
As of the 12th of November 2024, Genmab AS retains the Market Risk Adjusted Performance of (0.79), standard deviation of 1.44, and Risk Adjusted Performance of (0.09). Genmab AS technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Genmab AS's Outstanding Corporate Bonds
Genmab AS issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Genmab AS uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Genmab bonds can be classified according to their maturity, which is the date when Genmab AS has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| GENMMK 3882 19 APR 31 Corp BondUS37231BAA61 | View |
Understand Genmab AS's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Genmab AS's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.79) | |||
| Mean Deviation | 1.06 | |||
| Coefficient Of Variation | (769.10) | |||
| Standard Deviation | 1.44 | |||
| Variance | 2.07 | |||
| Information Ratio | (0.25) | |||
| Jensen Alpha | (0.24) | |||
| Total Risk Alpha | (0.51) | |||
| Treynor Ratio | (0.80) | |||
| Maximum Drawdown | 8.41 | |||
| Value At Risk | (2.38) | |||
| Potential Upside | 1.59 | |||
| Skewness | (0.64) | |||
| Kurtosis | 2.28 |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.79) | |||
| Mean Deviation | 1.06 | |||
| Coefficient Of Variation | (769.10) | |||
| Standard Deviation | 1.44 | |||
| Variance | 2.07 | |||
| Information Ratio | (0.25) | |||
| Jensen Alpha | (0.24) | |||
| Total Risk Alpha | (0.51) | |||
| Treynor Ratio | (0.80) | |||
| Maximum Drawdown | 8.41 | |||
| Value At Risk | (2.38) | |||
| Potential Upside | 1.59 | |||
| Skewness | (0.64) | |||
| Kurtosis | 2.28 |
Consider Genmab AS's intraday indicators
Genmab AS intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Genmab AS stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 36650.07 | |||
| Daily Balance Of Power | 0.2308 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 23.21 | |||
| Day Typical Price | 23.21 | |||
| Price Action Indicator | 0.05 | |||
| Period Momentum Indicator | 0.12 |
Genmab AS Corporate Filings
6K | 6th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
Genmab Stock media impact
Far too much social signal, news, headlines, and media speculation about Genmab AS that are available to investors today. That information is available publicly through Genmab media outlets and privately through word of mouth or via Genmab internal channels. However, regardless of the origin, that massive amount of Genmab data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Genmab AS news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Genmab AS relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Genmab AS's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Genmab AS alpha.
Genmab AS Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Genmab AS can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Genmab AS Historical Investor Sentiment
Investor biases related to Genmab AS's public news can be used to forecast risks associated with an investment in Genmab. The trend in average sentiment can be used to explain how an investor holding Genmab can time the market purely based on public headlines and social activities around Genmab AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Genmab AS's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Genmab AS and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Genmab AS news discussions. The higher the estimate score, the more favorable the investor's outlook on Genmab AS.
Genmab AS Corporate Management
| Birgitte MSc | Executive Officer | Profile | |
| Marisol Peron | Senior Affairs | Profile | |
| Christopher Cozic | Executive Officer | Profile | |
| Judith MD | Executive Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.38) | Earnings Share 1.04 | Revenue Per Share 30.6997 | Quarterly Revenue Growth 0.176 | Return On Assets 0.1095 |
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Genmab AS's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.